Design, synthesis and biological evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3β (GSK-3β)

Glycogen synthase kinase-3β (GSK-3β) plays a key role in type II diabetes and Alzheimer's diseases, to which non-ATP competitive inhibitors represent an effectively therapeutical approach due to their good specificity. Herein, a series of small molecules benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of GSK-3β have been designed and synthesized. The in vitro evaluation performed by luminescent assay showed most BTZ derivatives have inhibitory effects in micromolar scale. Among them compounds 6l, 6t and 6v have the IC50 values of 25.0 μM, 27.8 μM and 23.0 μM, respectively. Moreover 6v is devoid of any inhibitory activity in the assays to other thirteen protein kinases. Besides, SAR is analyzed and a hypothetical enzymatic binding mode is proposed by molecular docking study, which would be useful for new candidates design.

2,3-dihydro-2,5-disubstituted-1,5-benzothiazepin-4(5H)-one.Figure optionsDownload as PowerPoint slideHighlights
► A series of 2,3-dihydro-2,5-disubstituted-1,5-benzothiazepin-4(5H)-one were synthesized.
► These compounds showed GSK-3β inhibitory activities in vitro.
► Kinetic analysis showed compound 6v is non-ATP GSK-3β inhibitor.
► Molecular docking studies suggested the putative binding modes.